In the field of movement disorders, areas that have seen important advances in 2016 include the pathogenesis of Parkinson disease involving extra-CNS α-synuclein pathology, treatment of hyperkinetic disorders with novel dopamine-depleting drugs, and MRI-guided ultrasound surgery for the treatment of essential tremor.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Deweerdt, S. Parkinson's disease: 4 big questions. Nature 538, S17 (2016).
Thenganatt, M. A. & Jankovic, J. Parkinson disease subtypes. JAMA Neurol. 71, 499–504 (2014).
Marras, C. & Chaudhuri, K. R. Nonmotor features of Parkinson's disease subtypes. Mov. Disord. 31, 1095–1102 (2016).
Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167, 1469–1480 (2016).
Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72 (2016).
Gibbons, C. H., Garcia, J., Wang, N., Shih, L. C. & Freeman, R. The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease. Neurology 87, 505–512 (2016).
Deng, H. X. et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat. Genet. 48, 733–739 (2016).
Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 316, 40–50 (2016).
Jankovic, J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin. Pharmacother. 17, 2461–2470 (2016).
Elias, W. J. et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 375, 730–739 (2016).
J.J. has received research and/or training grants from the Michael J. Fox Foundation for Parkinson Research, the NIH, Neurocrine Biosciences, Prothena Biosciences and Teva Pharmaceuticals. He has served as a consultant or as an advisory committee member for Allergan, Pfizer and Teva Pharmaceuticals.
About this article
Cite this article
Jankovic, J. Progress in Parkinson disease and other movement disorders. Nat Rev Neurol 13, 76–78 (2017). https://doi.org/10.1038/nrneurol.2016.204
A wireless, implantable optoelectrochemical probe for optogenetic stimulation and dopamine detection
Microsystems & Nanoengineering (2020)
Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach
Acta Neurologica Belgica (2019)
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors